Dans ce manuscrit sont décrites de nouvelles procédures pour la synthèse stéréosélective d’un composé d’intérêt pharmacologique ainsi que leurs implémentations pour la production en continu. Plusieurs procédures de modification de catalyseurs hétérogènes commerciaux ont été développées et ont permis d’augmenter significativement la diastéréosélectivité de la réaction d’hydrogénation d’un intermédiaire de synthèse. Une voie de synthèse alternative par dérivatisation a également été développée, permettant d’atteindre une diastéréosélectivité pus élevée. De plus, des réacteurs modulaires dédiés à la réalisation de réactions triphasiques gas/liquide/solide sous haute pression ont été conçus. Un prototype a été fabriqué et a pu être utilisé pour les procédures d’hydrogénation développées. Enfin, un intermédiaire de synthèse a été préparé sans solvant ni additifs et avec une grande productivité en utilisant un microréacteur. / In this thesis, we present new procedures for the highly stereoselective synthesis of an active pharmaceutical ingredient and initiate their implementation in continuous flow for production. We developed several procedures for the highly diastereoselective hydrogenation reactions using chemically modified commercial heterogeneous catalysts. In addition, a three step reaction pathway through hydrolysis, highly diastereoselective hydrogenation reaction and conversion back to primary amide was developed to prepare. Modular high pressure continuous reactors have been designed and a prototype has been manufactured to perform the gas/liquid/solid triphasic hydrogenation reactions. Finally, we prepared a synthesis intermediate without solvents nor additives in continuous flow using a home-made micro-reactor, dramatically increasing the productivity of the process.

In the context of pharmaceutical development, it is abundantly clear that there is a need for greater understanding and control of crystalline phases. The field of crystal engineering is poised to address such issues and has matured into a paradigm for the supramolecular synthesis of new compounds with desired properties. Crystal structures are unpredictable by nature, however, the interactions that lead to crystal formation are becoming much more predictable. By means of model compound studies, the delineation of the hierarchy of hydrogen bonding between complementary functional groups or supramolecular heterosynthons can be accomplished. Competitive co-crystallization studies along with data extracted from the Cambridge Structural Database (CSD) can be utilized in understanding the reliability of supramolecular heterosynthons without the need for endless co-crystallization experiments. In effect, this ability to understand supramolecular heterosynthons can allow crystal engineers to rationally design co-crystals with a high rate of success. It has been suggested that pharmaceutical co-crystals could play a significant part in the future of API formulation since in principle they will outnumber pharmaceutical salts, polymorphs and solvates combined. The focus of this thesis is the understanding of the primary amide functional group and its hydrogen bonding capabilities; as well as the synthesis of model compounds in order to develop a blueprint for the design of pharmaceutical co-crystals using APIs that contain a primary amide functional group.